Broadening the definition of generalized anxiety disorder: Effects on prevalence and associations with other disorders in the National Comorbidity Survey Replication by Ruscio, Ayelet Meron et al.
Broadening the definition of generalized anxiety disorder: Effects on 
prevalence and associations with other disorders in the National 
Comorbidity Survey Replication 
  
 
Ayelet Meron Ruscio a,*, Wai Tat Chiu a, Peter Roy-Byrne b, Paul E. Stang c, Dan J. Stein d, 
Hans-Ulrich Wittchen e, Ronald C. Kessler a    
 
a Department of Health Care Policy, Harvard Medical School, USA 
b Department of Psychiatry and Behavioral Sciences, University of Washington School of Medicine, 
USA 
c Department of Health, College of Health Sciences, West Chester University and Galt Associates, 
USA 
d Department of Psychiatry, University of Cape Town, Republic of South Africa 
e Institute for Clinical Psychology and Psychotherapy, Dresden University of Technology, Germany 
   
 
 
Abstract  
 
Concerns have been raised that the DSM-IV requirements of 6-month duration, excessive worry, and 
three associated symptoms exclude a substantial number of people with clinically significant anxiety 
from a diagnosis of generalized anxiety disorder (GAD). We examined the implications of relaxing 
these three criteria for the estimated prevalence and predictive validity of GAD using nationally 
representative data from the US National Comorbidity Survey Replication. Relaxing all three criteria 
more than doubles the estimated prevalence of GAD. Broadly defined GAD significantly predicts the 
subsequent first onset of a wide range of temporally secondary disorders. The odds of secondary 
disorders are somewhat smaller for broadly defined than DSM-IV GAD, though few of these 
differences are statistically significant. Results suggest that subthreshold manifestations of GAD are 
significantly related to elevated risk of subsequent psychopathology. Further research is needed to 
determine whether broadening the current diagnostic criteria results in a more valid characterization of 
GAD.   
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The diagnostic definition of generalized anxiety disorder (GAD) has been a source of debate 
since the disorder was first introduced in the third edition of the Diagnostic and Statistical 
Manual of Mental disorders (DSM-III) (American Psychiatric Association, 1980). Given the 
challenges of distinguishing generalized anxiety from normal stress reactions and from other 
anxiety and mood disorders (Barlow, Blanchard, Vermilyea, Vermilyea, & DiNardo, 1986; 
Breslau & Davis, 1985; Brown, Barlow, & Liebowitz, 1994), it is perhaps not surprising that 
the definition of GAD has changed substantially with each subsequent DSM revision. DSM-
III defined GAD as 1 month of persistent anxiety accompanied by associated symptoms from 
three of four categories. DSM-III-R changed the requirements to 6 months of worry along 
with 6 of 18 associated symptoms to improve the validity of separation from normal anxiety 
and from anxiety that occurs secondary to other mental disorders (American Psychiatric 
Association, 1987). DSMIV made further changes aimed at sharpening the characterization of 
GAD by requiring that worry be excessive and uncontrollable (American Psychiatric 
Association, 1994). DSM-IV also stipulated that the worry in GAD must be associated with at 
least three of six symptoms of tension and vigilance, and cause significant distress or 
impairment.  
 
Although these changes have led to improved reliability of GAD diagnoses (Brown, Di 
Nardo, Lehman, & Campbell, 2001), debates persist about validity. Research has found that 
GAD lasting at least 1 month has very similar socio-demographic and clinical correlates 
(Kessler et al., 2005b) and is at least as heritable (Kendler, Neale, Kessler, Heath, & Eaves, 
1992) as GAD lasting 6 or more months, consistent with views of GAD as a chronic-recurrent 
condition that may manifest as brief, repeated episodes (Rickels & Rynn, 2001). Individuals 
who do not view their worry as excessive, but who meet all other DSM-IV GAD criteria, have 
been found to suffer substantial anxiety and report functional impairment, treatment seeking, 
and parental GAD at levels comparable to excessive worriers (Ruscio et al., 2005), seeming to 
support the omission of excessiveness from the ICD-10 (International Classification of 
Diseases, 10th ed.) (World Health Organization, 1993) definition of GAD. While growing 
evidence supports the narrowed DSM-IV focus on motor tension, vigilance and scanning 
symptoms as the core associated symptoms of GAD (Brown, Marten, & Barlow, 1995; 
Marten et al., 1993; Starcevic & Bogojevic, 1999; Starcevic, Fallon, & Uhlenhuth, 1994; 
Tracey, Chorpita, Douban, & Barlow, 1997), far less attention has been paid to the threshold 
of three symptoms, despite questions about the optimal number of required symptoms (Brown 
et al., 1995) and the unknown impact of different thresholds on the prevalence and correlates 
of GAD.  
 
These debates suggest that the GAD duration, excessiveness, and associated symptoms 
criteria may need to be revisited in the forthcoming revisions of DSM and ICD. However, 
before serious consideration is given to modifying these criteria, it is important to consider 
how such changes would influence the prevalence of GAD, and what implications these 
revisions would have for the relationship of GAD to other disorders (Maser, 1998). The 
finding that GAD often precedes and is a predictor of negative outcomes in disorders such as 
depression (e.g., Kessler et al., 1996; Schoevers, Deeg, van Tilburg, & Beekman, 2005) has 
underscored the clinical importance of its early diagnosis and treatment. It is critical that any 
proposed changes in criteria for GAD continue to have predictive validity.  
 
Our group recently began examining the implications of modifying the GAD duration 
(Kessler et al., 2005b) and excessiveness (Ruscio et al., 2005) criteria using data from the US 
National Comorbidity Survey Replication (NCS-R) (Kessler & Merikangas, 2004). Early 
results indicated that relaxing either of these criteria may bring into the GAD diagnosis a 
sizable number of individuals with a somewhat less severe, yet still clinically significant, 
GAD-like syndrome. These results, although suggestive, have left several issues unresolved. 
First, prior research studied the associations of modified GAD with other variables cross-
sectionally. To evaluate the implications of diagnostic changes for predictive validity, there is 
a need for research that takes a longitudinal perspective and that controls for other major 
features of GAD (uncontrollability, distress, impairment) that bear on its severity and may 
moderate its association with other disorders. Second, prior research focused on the duration 
and excessiveness criteria of GAD. There is a need to extend this research to other 
contentious GAD criteria that are likely to be re-examined in DSM-V. A logical extension is 
the GAD associated symptoms criterion, which was substantially revised in DSM-IV and 
remains a major source of discrepancy between the DSM and ICD definitions of the disorder. 
Given the key role of associated symptoms in informing clinicians’ pattern recognition and 
subsequent diagnostic judgments, it is crucial that we understand the implications of this 
criterion – and potential further refinements of this criterion – for the prevalence and 
predictive validity of GAD. Third, prior research studied the impact of altering each GAD 
criterion individually. As changes to diagnostic criteria are unlikely to be considered in 
isolation of one another, there is a need to evaluate the joint impact of modifying these criteria 
on the composition and utility of the GAD diagnosis.  
 
Although modifications may have the effect of either broadening or restricting a diagnostic 
definition, we consider only broadened GAD definitions here. A focus on broadened 
definitions is justified by observed similarities between DSM-IV and subthreshold GAD on 
such clinically important measures as disability and treatment seeking (Kessler et al., 2005b; 
Ruscio et al., 2005), suggesting that the current GAD definition may be missing clinically 
significant cases. A broadened definition may have the added advantage of allowing more 
patients to receive a definitive (rather than an NOS) diagnosis, allowing better identification 
and treatment of GAD— especially in non-specialty, primary care settings where many 
anxiety cases are seen. Finally, to the extent that GAD predicts the onset of other disorders, a 
broadened definition has the potential to identify a higher proportion of those who develop 
subsequent psychopathology. If the definition could be broadened without sacrificing 
predictive validity, the utility of the GAD diagnosis would be increased.  
 
The current paper uses data from the NCS-R to evaluate the implications of a broadened GAD 
diagnosis for estimates of prevalence and predictive validity. Increasingly broader definitions 
of GAD were constructed to examine the individual and joint effects of relaxing the duration, 
excessiveness, and associated symptoms requirements of DSM-IV. Aside from examining 
changes in prevalence, the main analytic focus is on the extent to which broadly defined GAD 
missing one or more of the above criteria predicts the subsequent first onset of temporally 
secondary DSM-IV disorders. This focus on prediction of secondary conditions was based 
partly on the assumption that a central way of defining clinical significance of subthreshold 
GAD is to determine whether it predisposes to other syndromes that are already considered 
clinically significant in the DSM system.  
 
1. Method  
 
1.1. Sample  
 
The NCS-R is a nationally representative, face-to-face survey of US household residents 
carried out between February 2001 and December 2003. The survey used a multi-stage 
clustered area probability sampling design and had a response rate of 70.9%. Recruitment 
began with a letter and study fact brochure followed by an in-person visit by an interviewer 
who described the study aims and procedures and obtained verbal (rather than written) 
informed consent, consistent with recruitment procedures of the baseline NCS (Kessler et al., 
1994). Respondents received $50 for their participation.  
 
All 9282 respondents were administered a Part I psychiatric diagnostic interview by a 
professional survey interviewer. Of these, a subset of 5692 respondents (including those who 
met lifetime criteria for any Part I disorder, plus a probability sample of other Part I 
respondents) was also administered a Part II interview assessing additional disorders and 
correlates. The present analyses were performed on this Part II sample, which was weighted 
to adjust for the differential probabilities of respondent selection as a function of household 
size, more intense recruitment of hard-to-recruit individuals, higher selection probabilities of 
Part I respondents with a lifetime disorder, and residual variation between sample and 
population distributions on several geographic and socio-demographic variables in the 2000 
US Census. Further details of the NCS-R sampling design and weighting procedures are 
provided elsewhere (Kessler et al., 2004).  
 
1.2. Diagnostic assessment  
 
Diagnoses were derived from Version 3.0 of the WHO Composite International Diagnostic 
Interview (CIDI 3.0) (Kessler & Ustun, 2004), a fully structured lay-administered diagnostic 
interview. Blind clinical re-interviews of a probability subsample of NCS-R respondents 
(Kessler, Berglund, Demler, Jin, & Walters, 2005a) found generally good concordance 
between DSM-IV diagnoses of anxiety, mood, and substance use disorders (impulse-control 
disorders were not evaluated) yielded by the CIDI 3.0 and by the Structured Clinical 
Interview for DSM-IV (SCID) (First, Spitzer, Gibbon, & Williams, 2002). GAD was 
diagnosed following DSM-IV criteria, but varying the duration, excessiveness, and associated 
symptoms required for a diagnosis. Duration was relaxed from 6+ months to 1+ months, 
excessiveness was relaxed to include excessive or non-excessive worry, and associated 
symptoms were relaxed from 3+ to 2+ Criterion C symptoms. To avoid the potentially 
obfuscating effects of uncertain GAD hierarchical exclusion criteria on the association of 
GAD with other disorders, we did not observe diagnostic hierarchies when assigning GAD 
diagnoses. All other disorders were diagnosed using DSM-IV criteria following diagnostic 
hierarchy rules.  
 
1.3. Other measures  
 
In addition to the DSM-IV GAD diagnosis, a measure of GAD severity was included in 
analyses. To construct the measure, a set of nested dichotomous variables representing 
uncontrollability, distress, and impairment associated with worry was submitted to a principal 
components analysis. The relative sizes of the unrotated eigenvalues for the first (5.9) and 
second (2.1) components, as well as consideration of simple structure, suggested a strong first 
principal component that can be interpreted as a general severity dimension. Consequently, 
these variables were submitted to a two-parameter item response theory (IRT) analysis using 
the BILOG software package (Scientific Software Inc., 1997), generating a continuous 
severity score that was trichotomized to divide the broadly defined GAD sample into roughly 
equal groups of mild (35%), moderate (32%), and severe (33%) cases.  
 
Several socio-demographic measures were included as covariates. These included age at 
interview (18–29, 30–44, 45–59, 60+), sex, race-ethnicity (Non-Hispanic White, Non-
Hispanic Black, Hispanic, other), education (student, 0–11 years, 12 years, 13–15 years, 16+ 
years), and marital status (currently married, previously married, never married).   
 
1.4. Statistical analysis  
 
Cross-tabulations were used to estimate prevalence and comorbidity for progressively broader 
definitions of GAD. Discrete-time survival analysis (Efron, 1988), with person-year as the 
unit of analysis, was used to examine the associations between variably defined GAD and the 
subsequent onset of temporally secondary disorders. The temporal order of GAD and other 
disorders was determined from retrospective age-of-onset reports. In an initial baseline model, 
associations were estimated separately for active GAD (in which the GAD episode was still 
ongoing when the later disorder began) versus remitted GAD (in which the GAD episode 
ended before the later disorder began). Within active and remitted subsamples, associations 
were also estimated separately for mild, moderate, and severe GAD based on respondents’ 
worst GAD episode in an effort to control for any confounding between the individual criteria 
under examination and overall disorder severity. Subsequent survival models focused on 
active GAD, estimating associations separately for DSM-IV GAD and for mutually exclusive 
subgroups who failed one or more GAD criteria. Survival coefficients were transformed to 
odds ratios (ORs) with 95%confidence intervals (CIs) for ease of interpretation. Multivariate 
significance was evaluated viaWaldx2 tests based on coefficient variance-covariance matrices 
adjusted for design effects using the Taylor series linearization method (Wolter, 1985). 
Statistical significance was evaluated at the .05 level using two-tailed tests.  
 
2. Results  
 
2.1. Prevalence and comorbidity of broadly defined GAD  
 
As expected, increasingly broader definitions of GAD are associated with increasing lifetime 
and 12-month prevalence of the disorder (Table 1). Prevalence increases by about 50–
60%when the duration criterion is relaxed from 6 months to 1 month and by about 40% when 
the excessiveness requirement is dropped. By contrast, requiring two rather than three 
associated symptoms has little effect on prevalence, as very few respondents who endorsed 
Criterion C symptoms (n = 1819) endorsed only two such symptoms (n = 140; even fewer 
endorsed just one associated symptom, n = 68). Relaxing both the duration and excessiveness 
criteria results in more than a doubling of GAD cases relative to the DSM-IV definition, to 
12.8% (lifetime) and 6.2% (12-month). Relaxing all three criteria raises the prevalence of 
GAD further to 13.7% (lifetime) and 6.6% (12-month).  
 
Increasingly broader definitions of GAD are associated with decreasing rates of comorbidity. 
Whereas 92% of those with the full DSM-IV GAD syndrome qualify for another lifetime 
DSMIV disorder assessed in the survey, the proportion of comorbid cases is 89–91% among 
those missing one GAD criterion, 87–89% among those missing two criteria, and 86% among 
those missing all three criteria. In an absolute sense, though, the proportion of comorbid cases 
is high for all GAD definitions considered here.  
 
2.2. Associations of GAD status and severity with the subsequent first onset of other disorders  
 
Active GAD more consistently predicts new onsets of subsequent DSM-IV disorders than 
does remitted GAD (Table 2). The median OR (inter-quartile range [IQR] in parentheses) is 
2.9 (1.9–3.8) for active GAD and 1.8 (1.0–2.6) for remitted GAD. The ORs for any mood 
disorder, any substance use disorder, and any disorder are significantly larger for active than 
remitted cases of broadly defined GAD.  
 
GAD severity also predicts the onset of secondary disorders, with more severe GAD 
associated with higher risk of secondary disorders. For most disorders, ORs increase 
monotonically over the three severity levels: moderate GAD is associated with greater relative 
odds of later disorders than mild GAD in 21 of 27 comparisons, whereas severe GAD is 
associated with greater odds than moderate GAD in 24 of 29 comparisons and mild GAD in 
30 of 30 comparisons. Nonetheless, severity of active GAD more consistently predicts the 
first onset of later anxiety and mood disorders (χ2 2 = 0.8-13.4, p < .001–.672) than later 
impulse-control or substance use disorders (χ21-2 = 0.0-6.9, p = .031–.984). Also, although 
the severity of remitted GAD is associated with later risk of any mood and any substance use 
disorder, it significantly predicts only one individual disorder: alcohol abuse with or without 
dependence (χ22 = 11.1, p = .004).  
 
2.3. Associations of variably defined GAD with the subsequent first onset of other disorders  
 
To study associations of variably defined GAD with later disorders, holding constant the 
effects of GAD status and severity, we estimated associations only for active GAD and 
controlled for GAD severity in addition to socio-demographics. DSM-IV GAD predicts the 
subsequent first onset of most disorders assessed even when severity is controlled (median 
OR = 2.6, IQR = 1.5–3.6), significantly so for 9 of 15 disorders (Table 3). The ORs are 
substantially higher in predicting mood (OR = 4.8) and anxiety (OR = 2.6) disorders than 
substance-use (OR = 1.8) and impulse-control (OR = 1.6) disorders.  
 
Overall, the full GAD syndrome is associated with a higher risk of subsequent disorders than 
is GAD in which one or more criteria are not met. The odds of new disorder onsets are highest 
for DSM-IVGAD, lower for GAD lasting less than six months (median OR = 1.7, IQR = 0.8–
2.9), and lower still for GAD involving only two associated symptoms (median OR = 1.5, 
IQR = 1.1–3.2) or non-excessive worry (median OR = 1.4, IQR = 0.7–1.7). Few of the 
differences in ORs between DSM-IV GAD and the subthreshold GAD subgroups are 
statistically significant. Nevertheless, declining ORs outnumber increasing ORs by at least 3:1 
across all disorders. Moreover, differences that are significant almost uniformly reveal lower 
odds of later disorders for partial than full GAD, with the most consistently diminished risk 
found for the bipolar spectrum (χ21 = 5.2-6.4, p = .011–.023). The sole exception is a 
substantially elevated risk of subsequent dysthymic disorder among respondents with non-
excessive worry (OR = 11.1, χ21 = 6.1, p = .014).  
 
2.4. Sensitivity analyses  
 
Sensitivity analyses were performed without controlling for GAD severity to see whether 
further significant differences would emerge between full and partial GAD (results not shown, 
but available on request). There was an across-the-board increase in the strength of 
associations between GAD and later disorders, both for the full DSM-IV syndrome (median 
OR = 4.0, IQR = 3.5–5.4) and for subgroups failing one or more of the three criteria (median 
OR = 2.7, IQR = 1.5–3.3). The overall pattern of results, though, was the same, with 
consistently smaller ORs associated with partial than full GAD and the same few disorders 
yielding significant results.  
 
To evaluate the robustness of these results, analyses were replicated within the more 
conservative subsample of respondents whose GAD episode preceded the onset of the 
secondary disorder by a minimum of 5 years. To enhance statistical power, we performed 
analyses using five broad categories of secondary disorders (anxiety, mood, impulse-control, 
substance-use, and any disorder). Consistent with earlier category-level results, DSM-IV 
GAD is a particularly strong predictor of first onsets of later mood disorders (OR = 6.2), a 
somewhat weaker predictor of later anxiety disorders (OR = 3.3), and a considerably weaker 
predictor of later substance-use (OR = 2.2) and impulse-control (OR = 1.6) disorders (Table 
4). The association with secondary mood disorders is weaker for three of the subthreshold 
GAD subgroups (OR = 0.9–2.8) than for the full GAD syndrome (OR = 6.2; χ21 = 2.6-6.8, p 
= .009–.109), an effect that earlier was shown to be due mainly to diminished risk for bipolar 
spectrum conditions. The exception is GAD without excessive worry (OR = 5.3, χ21 = 0.3, p 
= .575), which was found in earlier analyses to be due to elevated odds of dysthymic disorder 
offsetting the diminished odds of bipolar spectrum in this subgroup.  
 
3. Discussion  
 
The present findings must be interpreted in light of two important study limitations. First, all 
disorders included in these analyses were assessed by fully structured interviews administered 
by professional lay interviewers. Such interviews often generate more reliable diagnoses than 
semi-structured clinical interviews (Wittchen, 1994), and their prevalence estimates typically 
correspond well to diagnoses yielded by semi-structured clinical interviews (Kessler et al., 
2005a). Nevertheless, fully structured assessments limit the sorts of symptom clarification and 
cross-disorder questions that facilitate differential diagnosis, and this may have led to inflated 
associations between GAD and other disorders. Second, the temporal order of disorders was 
determined from retrospective age-of-onset reports. While we used a probing strategy that has 
been shown to improve recall of age of onset (Knauper, Cannell, Schwarz, Bruce, & Kessler, 
1999), there were doubtlessly residual errors, perhaps especially when distinguishing GAD 
from disorders with overlapping symptoms. To help mitigate this concern, we performed 
sensitivity analyses within subsamples reporting an onset of GAD at least 5 years before the 
comorbid disorder. Prospective longitudinal research would be needed to more definitively 
establish the temporal priority and prospective associations of GAD with other disorders.  
 
Within the context of these limitations, we found that broadening the GAD diagnosis in the 
three ways considered here would more than double the prevalence of the disorder. Most of 
the increase in prevalence comes from reducing the minimum duration to 1 month and, to a 
lesser extent, from eliminating the excessive worry requirement. Prevalence is minimally 
affected by requiring two rather than three associated symptoms. As the GAD definition is 
broadened, there is a slight but consistent decrement in the comorbidity of GAD with other 
disorders. This small decrement is apparent both in cross-sectional analyses of lifetime 
comorbidity and in longitudinal analyses estimating the odds of subsequent disorder onsets. 
However, few of the differences are sufficiently large to reach statistical significance. The 
overall pattern of results is the same regardless of whether GAD severity is controlled and 
even when the onsets of GAD and later disorders are separated by at least 5 years.  
 
These results join a growing dialogue about the optimal definition of GAD and the 
implications of revising some of its more controversial criteria in DSM-V and ICD-11. Our 
finding that relaxing these criteria leads to a sizable influx of new GAD cases inevitably raises 
questions about how high a rate of GAD is plausible and whether new cases are sufficiently 
severe to merit a diagnosis. It is clear that a broadened definition would lead to more 
widespread diagnosis than the GAD definitions in DSM-III, III-R, and IV, which have an 
estimated lifetime prevalence of 4–7% in the US population (Blazer, Hughes, George, Swartz, 
& Boyer, 1991; Grant et al., 2005; Kessler et al., 2005a; Wittchen, Zhao, Kessler, & Eaton, 
1994). Perhaps the more critical issue, though, is whether broadly defined GAD is likely to be 
more valid and clinically useful than DSM-IVGAD. Theorists disagree about the optimal 
diagnostic criteria for distinguishing normal from pathological general anxiety (Barlow & 
Wincze, 1998; Rickels & Rynn, 2001) and even about whether GAD is best conceived as a 
clinical syndrome, an anxious temperament type, or some combination of the two (Akiskal, 
1998; Rickels & Schweizer, 1995). Such disagreement is particularly pronounced in debates 
over the DSM-IV excessiveness criterion, which has been criticized for focusing on 
characterological anxiety and excluding people whose anxiety is associated with severe or 
chronic stress (Kessler & Wittchen, 2002). As in the case of depression, it is possible that 
distinguishing between endogenous and reactive anxiety is not useful for optimal diagnosis 
and treatment, and that a broader GAD construct would have greater clinical utility than the 
current narrowly defined syndrome. This is supported by indications that some cases falling 
below the GAD threshold are sufficiently similar to diagnosed cases that their inclusion may 
improve the validity of the diagnosis. Important similarities have previously been observed in 
functional impairment, socio-demographic features, family history of GAD, and other key 
correlates between the full GAD syndrome and GAD lasting as little as 1 month (Bienvenu, 
Nestadt, & Eaton, 1998; Carter, Wittchen, Pfister, & Kessler, 2001; Hunt, Issakidis, & 
Andrews, 2002; Kendler et al., 1992; Kessler et al., 2005b; Maier et al., 2000;Wittchen et al., 
2002) or involving non-excessive worry (Bienvenu et al., 1998; Ruscio et al., 2005).  
 
Consistent with these results, we found few significant differences in the associations of GAD 
with later disorders as a function of GAD duration or excessiveness. This finding casts further 
doubt on the DSM-IV 6-month duration and excessive-worry requirements, which appear to 
miss individuals who not only suffer from significant generalized anxiety, but have an 
elevated risk of developing additional disorders. While our results suggest similar conclusions 
about the requirement of three associated symptoms, it remains to be seen whether requiring 
fewer symptoms results in a clinically significant syndrome that is distinguishable from 
normal anxiety and transient stress reactions (Breslau & Davis, 1985; Spitzer & Williams, 
1984). An alternate possibility is that requiring more associated symptoms would result in a 
more valid GAD diagnosis that more powerfully predicts important outcomes. It is 
noteworthy in this regard that, in a clinical sample, Brown et al. (1995) found a threshold of 
four rather than three associated symptoms to maximize diagnostic sensitivity (i.e., 
correspondence with DSM-III-R GAD diagnoses) and specificity (i.e., distinction from other 
anxiety and mood disorders). Thus, there is a need for systematic study of all possible 
thresholds along the associated symptoms criterion in relation to a wide range of correlates in 
both clinical and community samples. Finally, and crucial for the issue of predictive validity, 
we found that individuals missing two or more GAD criteria did not differ significantly from 
diagnosed cases in their risk for most subsequent disorders. There is a need to examine the 
severity and disability experienced by such individuals, who in our sample comprised more 
than one-quarter of new cases of broadly defined GAD. There is also a need to determine 
whether early diagnosis and treatment of broadly defined GAD would be effective in 
decreasing symptoms, improving associated disability, and preventing the subsequent 
development of comorbid disorders.  
 
The present results run counter to concerns that less restrictive diagnostic criteria may lead to 
poorer differentiation of GAD from other disorders. If anything, we found the opposite effect: 
a slight reduction in associations with most other disorders as these GAD criteria are relaxed, 
with the most consistent reduction observed for later bipolar spectrum conditions. One 
possible explanation is that broadening the definition of GAD brings less severe cases into the 
diagnosis, and that lower rates of psychiatric comorbidity among less severe cases (Andrews, 
Slade, & Issakidis, 2002; Kessler, Chiu, Demler, Merikangas, & Walters, 2005c) diminish the 
comorbidity associated with GAD. This explanation is partly supported by the association of 
GAD severity with risk of later disorders, especially mood and anxiety disorders, in our 
sample. In contrast to this general pattern, we found the odds of subsequent dysthymic 
disorder to be substantially higher for non-excessive than excessive GAD. Previous studies 
have documented very strong associations between GAD and dysthymia in both community 
(Andrews et al., 2002) and clinical (Pini et al., 1997) samples, suggesting that dysthymia may 
be a particularly challenging boundary condition for GAD and that broadening the GAD 
diagnosis to include non-excessive worriers may further impede differentiation of these 
conditions. Alternatively, the higher odds may reflect a genuine increase in the co-occurrence 
of these two disorders. It is possible, for example, that an individual exposed to a chronic, 
objectively severe stressor may at first experience a proportionate (non-excessive) anxiety 
response and, over time, develop persistent feelings of hopelessness and dysphoria. Future 
research will need to distinguish these possibilities, and to consider further refinements to the 
GAD definition that facilitate its distinction from neighboring conditions and improve its 
detection and appropriate treatment.  
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